Tokio Marine appoints new CEO for Asia region; Ben Rudd made CEO of Prudential Wealth Management; HKEX hires from Prudential; Samsung SRA appoints former KIC infra head as CEO; HSBC Asset Management appoints senior vice president; Morningstar names head of manager research for Europe and Asia; PGIM adds ESG lead for Europe and Asia; Apex Group adds Singapore managing director; and more.
Lebourdais will shift to Sydney to work for Perennial. He will be responsible for research for the firmÆs Japanese Equities Trust which has delivered a net annual return of 5.3% over the past five years compared to 2.2% per annum growth recorded by the MSCI Japan Accumulation Index.
The Japanese Equities Trust is one of six funds run by Perennial which it calls boutiques. ôWe are keenly pursuing our business objective of developing all of our global boutiques,ö says Anthony Patterson, the firmÆs managing director. Perennial has total assets under management of A$20 billion ($15 billion).
Lebourdais has 14 years of industry experience and has previously worked for Lazard, BT Alex Brown and ABN AMRO.
His new job with Perennial starts on November 1.
China Life names Yuan Changqing as acting chairman; Future Super hires operations chief; China Life Franklin Asset Management CIO and deputy CEO leave; Willis Towers Watson has hired Kameswara Natakusumah as head of Indonesia; Prudential hires ex-Apac CEO for Allianz George David Sartorel as a non-executive director; Manulife IM hires into multi-asset solutions team in Asia; PineBridge Investments hires from BNY Mellon IM; and more.
The family office of Alibaba's co-founder likes to do its own hands-on due diligence and favours deals that can make a difference, rather than investments for the sake of ESG.
The Federal Reserve is now expected to hike interest rates as early as March and fed funds markets are pricing in up to four hikes in 2022.
The stock’s promising performance stands in sharp contrast to the less fortunate fates of other Chinese companies that have been affected by government clampdowns.